



## **Kerstin Kampa-Schittenhelm**

Medizinische Onkologie und Hämatologie · Dept. I

### **Kontakt**

Kerstin Kampa-Schittenhelm  
Rorschacherstrasse 95  
9007 St. Gallen

T +41 71 494 3574  
Kerstin.Kampa-Schittenhelm@h-och.ch

### **Bereiche**

Medizinische Onkologie und Hämatologie

## Publikationen (18)

Bajrami Saipi M, Ruiba A, Schittenhelm M, Blumenstock G, Győrffy B, Fazio S, Hafner M, Ahrens A, Aldinger L, Aellig V, Kavelaars F, Nombela-Arrieta C, Fend F, Valk P, Driessen C, Kampa-Schittenhelm K. High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML). *Cell Death Dis* 2024; 15:869.

Schittenhelm M, Kaiser M, Győrffy B, Kampa-Schittenhelm K. Evaluation of apoptosis stimulating protein of TP53-1 (ASPP1/PPP1R13B) to predict therapy resistance and overall survival in acute myeloid leukemia (AML). *Cell Death Dis* 2024; 15:25.

Kliebhan J, Besse A, Kampa-Schittenhelm K, Schittenhelm M, Driessen C. Mutant driving the Warburg Effect in Mantle Cell lymphoma. *Clin Case Rep* 2022; 10:e6296.

Tsintari V, Walter B, Fend F, Overkamp M, Rothermundt C, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS). *BMC cancer* 2022; 22:725.

Rieger I, Tsintari V, Overkamp M, Fend F, Lopez C, Schittenhelm M, Kampa-Schittenhelm K. ASPP2 $\kappa$  Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis. *Front Mol Biosci* 2021; 8:727203.

Kampa-Schittenhelm K, Vogel W, Schleicher E, Bonzheim I, Mau-Holzmann U, Illing B, Akmut F, Ganief T, Dreher S, Blumenstock G, Haeusser L, Bühring H, Tsintari V, Bonin M, Haverkamp T, Schittenhelm M. Epigenetic activation of O-linked  $\beta$ -N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia. *EBioMedicine* 2020; 54:102678.

Schittenhelm M, Lopez C, Fend F, Mau-Holzmann U, Illing B, Akmut F, Bajrami Saipi M, Federmann B, Tsintari V, Walter B, Kampa-Schittenhelm K. Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia. *EBioMedicine* 2019; 42:340-351.

Kampa-Schittenhelm K, Vogel W, Bonzheim I, Fend F, Horger M, Kanz L, Soekler M, Schittenhelm M. Dasatinib overrides the differentiation blockage in a patient with mutant- D816V positive CBF $\beta$ -MYH11 leukemia. *Oncotarget* 2018; 9:11876-11882.

Kampa-Schittenhelm K, Frey J, Haeusser L, Illing B, Pavlovsky A, Blumenstock G, Schittenhelm M. Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia. *Oncotarget* 2017; 8:82897-82909.

Kampa-Schittenhelm K, Salitzky O, Akmut F, Illing B, Kanz L, Salih H, Schittenhelm M. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns. *BMC cancer* 2016; 16:25.

Schittenhelm M, Illing B, Akmut F, Rasp K, Blumenstock G, Döhner K, Lopez C, Kampa-Schittenhelm K. Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure. *PloS one* 2013; 8:e80193.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Rasp K, Illing B, Döhner H, Döhner K, Schittenhelm M. Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. *Mol Cancer* 2013; 12:46.

Kampa-Schittenhelm K, Heinrich M, Akmut F, Döhner H, Döhner K, Schittenhelm M. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Mol Cancer* 2013; 12:19.

Krusch M, Salih J, Schlicke M, Baessler T, Kampa-Schittenhelm K, Mayer F, Salih H. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. *J Immunol* 2009; 183:8286-94.

Kampa-Schittenhelm K, Bonin M, Lopez C. New insights into the expanding complexity of the tumor suppressor ASPP2. *Cell Cycle* 2009; 8:2871-6.

Schittenhelm M, Kampa-Schittenhelm K, Yee K, Heinrich M. The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin. *Cell Cycle* 2009; 8:2621-30.

Kampa-Schittenhelm K, Acoba J, Chen D, Gay J, Lee H, Beemer K, Padiernos E, Boonmark N, Zhu Z, Fan A, Bailey A, Fleming W, Corless C, Felsner D, Naumovski L, Lopez C. Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds. *Proc Natl Acad Sci U S A* 2009; 106:4390-5.

Zhu Z, Ramos J, Kampa-Schittenhelm K, Adimoolam S, Sirisawad M, Yu Z, Chen D, Naumovski L, Lopez C. Control of ASPP2/(53BP2L) protein levels by proteasomal degradation modulates p53 apoptotic function. *J Biol Chem* 2005; 280:34473-80.

## Projekte (0)

Keine Resultate gefunden.

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)